MODERNA-MERCK VACCINE CUTS ODDS OF SKIN CANCER RECURRENCE IN HALF, STUDY FINDS

Summary from the TLDR newsletter

An ongoing randomized vaccine trial involving 157 patients with high-risk stage III/IV melanoma is showing promising results. Those who received the vaccine were 49% less likely to die or have their cancer come back after three years than those who only received treatment with a cancer drug. Phase 3 trials of the vaccine have begun.